The allegations by the U.S. government's Consumer Product Safety
Commission (CPSC) are the latest in a series of regulatory troubles
facing Indian pharmaceutical firms in their biggest export market,
the United States.
In a U.S. stock exchange filing this week, Dr Reddy's said the CPSC
planned to seek civil penalties against the company for allegedly
violating rules intended to prevent children from ingesting harmful
The company said any unfavorable outcome could result in
"significant liabilities" and added that it disagreed with the
Indian drugmakers have suffered a string of drug recalls and
manufacturing quality-related issues that have hurt the reputation
of the $15 billion-a-year industry as a supplier of cheap generic
drugs, and led to increased scrutiny from regulators.
(Reporting by Zeba Siddiqui in Mumbai; Editing by Miral Fahmy)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column]